{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:ema.tabrecta:0 retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Aema.tabrecta%3A0",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.00369,
    "timestamp_received": "2026-04-24T15:54:23.258301+00:00Z",
    "timestamp_returned": "2026-04-24T15:54:23.261991+00:00Z",
    "trace_id": "ebc612c5-37ca-4082-af8c-45ad8d087f71"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-04-09"
  },
  "data": [
    {
      "id": "ind:ema.tabrecta:0",
      "indication": "Tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.",
      "initial_approval_date": "2022-09-21",
      "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/tabrecta-epar-public-assessment-report_en.pdf",
      "description": "The European Medicines Agency (EMA) has authorized capmatinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with alterations leading to mesenchymal-epithelial transition factor gene exon 14 (MET exon 14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.",
      "raw_biomarkers": null,
      "raw_cancer_type": "Non-small cell lung cancer",
      "raw_therapeutics": "Tabrecta (capmatinib)",
      "icd10": null,
      "regimen_code": null,
      "reimbursement_category": null,
      "reimbursement_date": null,
      "reimbursement_details": null,
      "date_regular_approval": null,
      "date_accelerated_approval": null,
      "document": {
        "id": "doc:ema.tabrecta",
        "type": "Document",
        "documentType": "Regulatory approval",
        "name": "Tabrecta (capmatinib) [product information]. EMA.",
        "title": null,
        "aliases": [],
        "description": "Novartis Europharm Limited. Tabrecta (capmatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tabrecta-epar-product-information_en.pdf. Revised January 2023. Accessed March 23, 2024.",
        "urls": [
          "https://www.ema.europa.eu/en/medicines/human/EPAR/tabrecta",
          "https://www.ema.europa.eu/en/documents/product-information/tabrecta-epar-product-information_en.pdf"
        ],
        "doi": null,
        "pmid": null,
        "extensions": [
          {
            "name": "agent",
            "value": {
              "id": "ema",
              "type": "Agent",
              "agentType": "organization",
              "name": "European Medicines Agency",
              "description": "Regulatory agency that approves medicines for use in the European Union.",
              "extensions": [
                {
                  "name": "last_updated",
                  "value": "2025-10-01",
                  "description": ""
                },
                {
                  "name": "url",
                  "value": "https://www.ema.europa.eu/en/medicines",
                  "description": ""
                }
              ]
            },
            "description": "The organization that published this document."
          },
          {
            "name": "company",
            "value": "Novartis Europharm Limited.",
            "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_brand",
            "value": "Tabrecta",
            "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_generic",
            "value": "capmatinib",
            "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "first_publication_date",
            "value": "2022-09-21",
            "description": "The publication date for the initial version of this document."
          },
          {
            "name": "identification_number",
            "value": null,
            "description": "Identification number used by the publishing organization."
          },
          {
            "name": "publication_date",
            "value": "2023-01-25",
            "description": "The publication date for the document."
          },
          {
            "name": "status",
            "value": "Active",
            "description": "Whether this document is Active or Deprecated within moalmanac-db."
          }
        ]
      }
    }
  ]
}